BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10804753)

  • 1. [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
    Dobrilla G; Capurso L
    Recenti Prog Med; 2000 Apr; 91(4):191-210. PubMed ID: 10804753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
    Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL
    Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lansoprazole: a proton pump inhibitor.
    Garnett WR
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin.
    Maiden LP; Harris AW
    N Engl J Med; 2002 Nov; 347(20):1623-4; author reply 1623-4. PubMed ID: 12432054
    [No Abstract]   [Full Text] [Related]  

  • 14. [25 years of gastric acid blockers].
    Lamers CB
    Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
    Kim JD
    J Fam Pract; 2002 Apr; 51(4):384. PubMed ID: 11978268
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
    Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
    Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
    Arnold R
    Fortschr Med; 1994 Jan; 112(1-2):44-5. PubMed ID: 8144120
    [No Abstract]   [Full Text] [Related]  

  • 19. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
    Asaka M; Kato M; Sugiyama T; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S;
    J Gastroenterol; 2003; 38(4):339-47. PubMed ID: 12743773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term course of reflux symptoms following Helicobacter pylori eradication].
    Peitz U; Raps S; Plein K; Leodolter A; Hotz Dagger J; Malfertheiner P
    Dtsch Med Wochenschr; 2004 Mar; 129(13):671-5. PubMed ID: 15026962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.